Swiss company Dr Mueller, a leading provider of filtration equipment for pharmaceutical manufacturers worldwide, will be among the exhibitors ...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the coming five years to bolster its presence ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.